Table 1 Patient demographics and clinical characteristics and probability of VTE and major bleeding
| Â | Â | N (%) | VTE | PE | Bleeding |
|---|---|---|---|---|---|
Total | Â | 2553 | 208 (8.21) | 93 (3.6) | 341 (13.4) |
Age | <  55 | 398 (15.6) | 45 (11.3) | 18 (4.5) | 42 (10.8) |
|  | 55–65 | 724 (28.4) | 73 (10.1) | 27 (3.7) | 83 (11.5) |
|  | 65–75 | 703 (27.5) | 54 (7.7) | 24 (3.4) | 103 (14.7) |
|  | ≥ 75 | 728 (28.5) | 36 (5.0) | 24 (3.3) | 112 (15.4) |
Gender | Male | 1765 (69.1) | 141 (8.0) | 54 (3.1) | 260 (14.7) |
| Â | Female | 788 (30.9) | 67 (8.5) | 39 (4.9) | 81 (10.3) |
Charlson’s comorbidity Index | ≤ 5 | 1811 (70.9) | 159 (8.8) | 37 (2.7) | 239 (13.2) |
|  | >  5 | 742 (29.1) | 49 (6.6) | 56 (4.8) | 102 (13.8) |
Metastatic | No | 1018 (39.9) | 41 (4.0) | 16 (1.6) | 125 (12.3) |
| Â | Yes | 1535 (60.1) | 167 (10.9) | 77 (5.0) | 216 (14.1) |
VTE concomitant with cancer diagnosis | No | 2489 (97.5) | 201 (8.1) | 90 (3.6) | 329 (13.2) |
| Â | Yes | 64 (2.5) | 7 (10.9) | 3 (4.7) | 12 (18.8) |
Anticoagulant or antiplatelet treatment | No | 1706 (66.8) | 158 (76.0) | 71 (76.3) | 199 (58.4) |
Yes | 847 (33.2) | 50 (24.0) | 22 (23.7) | 142 (41.6) | |
Anticoagulant therapy | No | 2338 (91.6) | 195 (8.3) | 86 (3.7) | 293 (12.5) |
| Â | Yes | 215 (8.4) | 13 (6.1) | 7 (3.3) | 48 (22.3) |
Antiplatelet therapy | No | 1851 (72.5) | 168 (9.1) | 78 (4.2) | 227 (12.3) |
| Â | Yes | 702 (27.5) | 40 (5.7) | 15 (2.1) | 114 (16.2) |
NSAID therapy | No | 2255 (88.3) | 175 (7.8) | 80 (3.6) | 311 (13.8) |
| Â | Yes | 298 (11.7) | 33 (11.1) | 13 (4.4) | 30 (10.1) |